{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:14:13Z","timestamp":1786990453875,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijcard.2019.01.052","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T01:55:22Z","timestamp":1547690122000},"page":"99-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy"],"prefix":"10.1016","volume":"280","author":[{"given":"Rachele","family":"Adorisio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Calvieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Cantarutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Catteruccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Baban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Amodeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.01.052_bb0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ehf2.12165","article-title":"Clinical profiles and prognosis of acute heart failure in adult patients with dystrophinopathies on home mechanical ventilation","volume":"4","author":"Fayssoil","year":"2017","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/mt.2011.59","article-title":"Current status of pharmaceutical and genetic therapeutic approaches to treat DMD","volume":"19","author":"Pichavant","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0015","first-page":"1475","article-title":"Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options","volume":"11","author":"LoMauro","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4187\/respcare.00831","article-title":"Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival","volume":"56","author":"Bach","year":"2011","journal-title":"Respir. Care"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0025","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0030","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.104.528281","article-title":"Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy","volume":"112","author":"Jefferies","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mus.24163","article-title":"Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"50","author":"Spurney","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0040","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1253\/circj.70.991","article-title":"Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy","volume":"70","author":"Kajimoto","year":"2006","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0045","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2169\/internalmedicine.49.3259","article-title":"Carvedilol can prevent cardiac events in Duchenne muscular dystrophy","volume":"49","author":"Matsumura","year":"2010","journal-title":"Intern. Med."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jjcc.2008.08.013","article-title":"Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy","volume":"53","author":"Ogata","year":"2009","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00246-007-9113-z","article-title":"Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy","volume":"29","author":"Rhodes","year":"2008","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0060","first-page":"691","article-title":"Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy","volume":"41","author":"Saito","year":"2001","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2012.02.064","article-title":"Effects of angiotensin-converting enzyme inhibitors and\/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy","volume":"110","author":"Viollet","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0070","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1136\/heartjnl-2017-311269","article-title":"A current approach to heart failure in Duchenne muscular dystrophy","volume":"103","author":"D'Amario","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0075","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","article-title":"The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1067\/mem.2002.121483","article-title":"B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea","volume":"39","author":"Harrison","year":"2002","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification","volume":"7","author":"Lang","year":"2006","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jmri.24011","article-title":"ACR guidance document on MR safe practices: 2013","volume":"37","author":"Expert Panel on MRS","year":"2013","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fped.2017.00013","article-title":"Results of late gadolinium enhancement in children affected by dilated cardiomyopathy","volume":"5","author":"Muscogiuri","year":"2017","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0105","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijcard.2016.08.135","article-title":"Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: a chance for slowing progression of heart failure?","volume":"223","author":"De Benedittis","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0120","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0002-8703(99)70414-X","article-title":"Cardioprotection for Duchenne's muscular dystrophy","volume":"137","author":"Ishikawa","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2010.10.125","article-title":"Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL","volume":"146","author":"Ceconi","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12968-014-0081-1","article-title":"Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients","volume":"16","author":"Florian","year":"2014","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000322905","article-title":"Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis","volume":"117","author":"Busseuil","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2019.01.052_bb0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fphar.2016.00408","article-title":"The protective effects of Ivabradine in preventing progression from viral myocarditis to dilated cardiomyopathy","volume":"7","author":"Yue-Chun","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.nmd.2008.03.002","article-title":"Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy","volume":"18","author":"Markham","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1532-429X-13-60","article-title":"Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance","volume":"13","author":"Hor","year":"2011","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ijcard.2019.01.052_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001338","article-title":"Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy","volume":"4","author":"Tandon","year":"2015","journal-title":"J. Am. Heart Assoc."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318356110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318356110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:40:55Z","timestamp":1759092055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318356110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":32,"alternative-id":["S0167527318356110"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.052","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}